Condition: Drug Susceptible Pulmonary Tuberculosis · Sponsor: Gates Medical Research Institute
The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
This description comes directly from the study's public registry record.
Gates MRI · +857-702-2108 · Clinical.trials@gatesmri.org
Gates MRI · +1-866-789-5757 · Clinical.trials@gatesmri.org
Always discuss trial participation with your own doctor first.
| Wits RHI - Shandukani Research | Johannesburg, Gauteng, South Africa | Recruiting |
| The Aurum Institute Clinical Research Site - Pretoria | Pretoria, Gauteng, South Africa | Recruiting |
| TASK Clinical Research Centre | Cape Town, Western Cape, South Africa | Recruiting |
| UCT Lung Institute (Pty) Ltd (Centre for TB Research Innovation) | Cape Town, Western Cape, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07517445